IFT57 and cancer: To further examine the degree to which CD47 and IFT57 are coregulated in cancers and identify biomarkers to distinguish the functions of IFT57 and CD47 in these cancers, we used CRISPR/Cas9-targeted knockdown of IFT57 or CD47 in a thyroid carcinoma cell line to identify transcripts sensitive to altered IFT57 expression.